We finished November slightly lower than the AORD, which had a stellar month, driven in large part by the banks and Qantas, who got a boost now that the Rona vaccine is on the horizon. However our performance since inception (9/19) is still better than double the AORD, which is our long-term goal.

What? A free weekly investing newsletter? Oh yes please.

Every Monday we publish a newsletter with updates on our podcast and portfolio activity. Sign up now to get your copy completely free!